Mondaq Asia Pacific: Food, Drugs, Healthcare, Life Sciences
Corrs Chambers Westgarth
The Australian aged care sector is experiencing a period of rapid change, with five emerging trends as a key 2015 focus.
King & Wood Mallesons
This article reviews highlights of the recent amendments and discusses the provisions of the Second Revised Amendment.
King & Wood Mallesons
This series of regulatory actions demonstrate efforts to strengthen the administration of medical devices and equipment.
Ropes & Gray LLP
The CFDA expects all device companies to comply with the New GMP and GSP rules as long as they intend to sell the products in China.
Ropes & Gray LLP
On November 21, 2014, China Food and Drug Administration ("CFDA") released a Draft Guidance on Multi-Regional Clinical Trials (Provisional) ("Guidance") for public comments through December 21.
King & Wood Mallesons
Reflections focus on the topics of: response time; response attitude; internal PR teams and official press conferences.
Ropes & Gray LLP
The Center for Drug Evaluation of the China Food and Drug Administration published a long-awaited guidance document for companies seeking to develop biosimilars.
Broad & Bright
People are growing increasingly conscientious about their health, and the pharmaceutical industry has become an important part of the national economy.
Ropes & Gray LLP
China’s health authority, the National Health and Family Planning Commission, released the Administrative Measures for the Clinical Study Projects of Medical Institutions.
Foley & Lardner
This post is the second in Foley’s blogs on China telemedicine and the first in the blog series, "Realizing the Potential of Telemedicine in China," meant to address top issues facing U.S. companies looking to enter the Chinese telemedicine market. We hope to expand the series to include additional issues.
Foley & Lardner
Telemedicine providers and vendors doing business in China, whether based in China, the United States, or elsewhere, received new guidance on the use of telemedicine.
Jones Day
Two individuals will be prosecuted shortly in Shanghai for conducting illegal investigations and purchase of personal information in China.
Jones Day
China continues to struggle in its efforts to improve food safety regulation and oversight, in the wake of a succession of food safety problems.
Ropes & Gray LLP
The amended Regulation for the Supervision and Administration of Medical Devices (the "Regulation," also known as the State Council Order No. 650), which came into force on June 1, 2014, set the new framework for China’s device regulatory regime.
King & Wood Mallesons
This newsletter discusses the differences between the Amendment and the Revised Amendment, and the underlying rationale.
DaHui Lawyers
A number of recent commercial bribery cases concerning multinational pharmaceutical companies have drawn extensive attention.
Eiger
This article outlines the implications of the new Free Trade Agreement between China and Switzerland in relation to the trade in medical devices.
King & Wood Mallesons
The China FDA has recently promulgated the Provisions on the Food and Drug Administrative Penalty Procedure.
King & Wood Mallesons
The Revised Regulations will come into effective on 1 June 2014, presenting some major changes.
Benesch Law
On December 26, 2013, the Commission promulgated Nine Prohibitions to Strengthen Ethical Conduct in the Healthcare Industry Circular [2013] No. 49.
Most Popular Recent Articles
Corrs Chambers Westgarth
The Australian aged care sector is experiencing a period of rapid change, with five emerging trends as a key 2015 focus.
Singh & Associates
Indian Pharmaceutical Industry is at present, at its most progressive era where it has witnessed a robust growth over the past few years.
Nishith Desai Associates
April 6, 2014 was a red letter day for the Indian pharmaceutical industry as Sun Pharmaceutical Industries Limited ("Sun Pharma") and Ranbaxy Laboratories Limited ("Ranbaxy") announced that they had entered into definitive documents for merger of Ranbaxy with Sun Pharma ("Transaction").
Krishna & Saurastri Associates
Pharmaceutical giant Bayer filed an appeal against the granting of a compulsory licence for Nexavar to Indian generic manufacturer Natco...
Singh & Associates
With the objective to improvise and endow with the basic health care and availability of basic medicines at an affordable price across the country, the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, , notified the Drug (Prices Control) Order 2013("DPCO 2013") in May 2013, which may fluctuate the pricing of 348 essential medicines.
Singh & Associates
In the last few years, the Indian pharmaceutical sector has seen an immense growth both in terms of domestic and international stratum.
ZEUS Law Associates
In its Cabinet Note in December, 2014, the Government of India proposed significant amendments to the Consolidated Foreign Direct Investment Policy, 2014 (''FDI Policy'') with respect to India's medical device industry.
Norton Rose Fulbright Australia
The decision considers whether and to what extent a duty of care is owed by a hospital after the discharge of a patient.
Singh & Associates
Hon'ble Apex Court has recently awarded a historic verdict having a major impact on medical negligence and standard of medical care in India.
Ropes & Gray LLP
The CFDA expects all device companies to comply with the New GMP and GSP rules as long as they intend to sell the products in China.
Article Search Using Filters
Related Topics
Popular Authors
Popular Contributors
Tools
Font Size:
Translation
Channels
Mondaq on Twitter